Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05344274 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Retinal Blood Flow and Autoregulation

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 2026 to Sep 2027v6
  2. 2 versions Re-verified since Apr 30, 2023, no change to tracked fieldsv4-v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 4 of 4 sites
    v3
  4. Start date: May 2022 to May 23, 2022
    • Study description expanded, about 5 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
Trial Details
NCT Number NCT05344274
Lead Sponsor University of Maryland, Baltimore
Conditions
(from sponsor)		 Glaucoma
Related terms Glaucoma
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov